Market Overview

UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, $60 PT; Attractive Orphan Platform

Related GEVA
UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step
UPDATE: Synageva Biopharma™ Announces 2M Share Proposed Public Offering of Its Common Stock

Canaccord Genuity initiates its coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy rating and a price target of $90.

Canaccord Genuity says, "Early but encouraging SBC--102 proof --102 proof--of --of- ofof-concept data: --concept data: The lateonset LAL-D Phase 1/2 trial data presented to date has been impressive – rapid and significant decreases in hepatic enzymes indicate that SBC-102 is having the predicted biochemical role in combating liver abnormalities."

GEVA closed at $38.50 on Friday.

Posted-In: Canaccord GenuityAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (GEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free